Crossbow Therapeutics Raises $77M in Series B Funding

Why It Matters

The capital infusion accelerates development of off‑the‑shelf T‑cell engagers that could offer safer, more scalable alternatives to CAR‑T therapies, reshaping the cancer immunotherapy market.

Key Takeaways

• $77M Series B funding led by Taiho Ventures, Arkin BioCapital.
• CBX‑250 enters Phase 1 for multiple leukemias, data due 2026.
• TCR‑mimetic antibodies aim to reduce immune‑related toxicity.
• Pipeline includes CBX‑663 targeting telomerase in 95% cancers.
• Investors include Pfizer Ventures, Polaris Partners, expanding biotech backing.

Pulse Analysis

TCR‑mimetic antibodies are emerging as a pragmatic bridge between traditional monoclonal antibodies and cell‑based therapies like CAR‑T. By engineering antibodies that mimic T‑cell receptors, companies can direct immune cells to cancer targets without the manufacturing complexity and patient‑specific logistics of autologous cell products. This approach promises a more cost‑effective, off‑the‑shelf solution, addressing a key barrier to broader adoption of immunotherapy across community hospitals and emerging markets.

Crossbow’s lead asset, CBX‑250, leverages this technology to recognize a leukemia‑specific peptide fragment, delivering potent cytotoxicity while sparing normal tissue in animal studies. The upcoming Phase 1 trial will enroll patients with acute and chronic myeloid leukemias, myelodysplastic syndromes, and chronic myelomonocytic leukemia, aiming to validate safety and early efficacy signals by year‑end. Parallelly, CBX‑663 targets telomerase reverse transcriptase, a near‑universal cancer antigen, positioning the company to address both hematologic and solid tumors with a single bispecific platform.

The $77 million raise underscores growing investor confidence in next‑generation T‑cell engagers. Backers such as Taiho Ventures, Arkin BioCapital, and Pfizer Ventures signal that major pharma sees strategic value in diversifying beyond CAR‑T. This funding not only de‑risks Crossbow’s clinical milestones but also intensifies competition in a space where safety, manufacturability, and scalability are paramount. If successful, Crossbow could catalyze a shift toward antibody‑based T‑cell redirection as a mainstream cancer treatment modality.

Deal Summary

Crossbow Therapeutics announced a $77 million Series B financing co‑led by Taiho Ventures and Arkin BioCapital, with participation from MPM BioImpact, Pfizer Ventures, Polaris Partners and other investors. The capital will fund the development of its TCR‑mimetic antibody candidates, including lead drug CBX‑250, and support its Phase 1 trial. The round highlights growing investor interest in T‑cell engager immunotherapies.